|
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
It is now apparent that deregulation of beta-catenin signaling is an important event in the genesis of a number of malignancies, such as colon cancer, melanoma, hepatocellular carcinoma, ovarian cancer, endometrial cancer, medulloblastoma pilomatricomas, and prostate cancer. beta-catenin mutations appear to be a crucial step in the progression of a subset of these cancers, suggesting an important role in the control of cellular proliferation or cell death.
|
10580987 |
1999 |
|
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
As a translational research tool, OCP identified adaptive CTNNB1 amplifications/mutations in treated prostate cancers.
|
25925381 |
2015 |
|
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Although evidence of abnormal activation of the Wnt pathway in prostate cancer has been demonstrated by several groups, APC and beta-catenin mutations are infrequent.
|
18514389 |
2009 |
|
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Beta-catenin mutations in human prostate cancer.
|
9635571 |
1998 |
|
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We therefore conclude that, in contrast to prostate cancer, mutations in the PTEN gene seem not to affect cellular distribution of the beta-catenin protein in endometrial carcinomas.
|
15492994 |
2004 |
|
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Because mutations in adenomatous polyposis coli, β-catenin and other components of the destruction complex are generally rare in PCas, other mechanisms of aberrant Wnt signaling activation have been speculated.
|
25893287 |
2016 |
|
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
APC or CTNNB1 mutations in colorectal, endometrial and prostate cancers activate the WNT/β-catenin signaling cascade.
|
28731148 |
2017 |
|
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The presence of somatic beta-catenin mutations in some prostate cancers implies that aberrant WNT signaling is involved in the cancer development.
|
18819930 |
2008 |
|
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Because activating mutations in the beta-catenin gene are rare in prostate cancer, we have looked for altered expression of other components of the Wnt signaling pathway in prostate cancer cells.
|
15520198 |
2004 |
|
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We selected and genotyped 13 tagged single-nucleotide polymorphisms (tSNP) to predict common variants across entire APC and CTNNB1 genes in 307 patients with clinically localized PCa who received RP and 371 unaffected controls.
|
19777185 |
2010 |
|
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers.
|
11921277 |
2002 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
PBK/TOPK enhances aggressive phenotype in prostate cancer via β-catenin-TCF/LEF-mediated matrix metalloproteinases production and invasion.
|
25909225 |
2015 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
CTD_human |
The long tail of oncogenic drivers in prostate cancer.
|
29610475 |
2018 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Heightened expression of the Trop2 intracellular domain promotes stem/progenitor self-renewal through signaling via β-catenin and is sufficient to initiate precursor lesions to prostate cancer in vivo.
|
23070813 |
2012 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Roles and regulation of Wnt signaling and beta-catenin in prostate cancer.
|
16023783 |
2006 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Moreover, we detected the endogenous protein complex containing ICAT, AR, and β-catenin in prostate cancer cells using immunoprecipitation assays.
|
21885566 |
2011 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Because we had demonstrated that PrKD1 is the only known kinase to phosphorylate threonine 120 (T120) of beta-catenin in prostate cancer resulting in increased nuclear beta-catenin, we explored the role of beta-catenin in gene regulation of <i>PrKD1</i>.
|
29108267 |
2017 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
This study establishes the functional significance of combined dysregulation of PKD1 and E-cadherin in PC and that their effect on cell growth is mediated by beta-catenin.
|
17979146 |
2008 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
β-catenin has also been reported to form complex with AR and thus augment AR signaling in PCa.
|
31027362 |
2019 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Pharmacological inhibition of β-catenin nuclear translocation using compounds ICG001 and IWR-1 restored HLEC tight-junction integrity and inhibited prostate cancer cell transendothelial migration in vitro and lung metastasis in vivo.
|
29755115 |
2018 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Wnt is a complex signaling pathway whose endpoint involves activation of transcription from LEF-1/TCF transcription factors and it is known to be involved in the development and progression of numerous human epithelial tumors including prostate cancer. beta-catenin protein, a particularly critical molecular component of canonical Wnt signaling is now known to promote androgen signaling through its ability to bind to the AR protein in a ligand-dependent fashion and to enhance the ability of liganded AR to activate transcription of androgen-regulated genes.
|
16741972 |
2006 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
In addition, CDC20 combined with CD44 or β-catenin can serve as an important indicator for prognosis of patients with prostate cancer.
|
30904606 |
2019 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
CLCA2 promoted PCa cell adhesion inhibiting epithelial-mesenchymal transition (EMT) and activating CTNNB1 together with epithelial marker (CDH1) induction, and mesenchymal markers (SNAI2 and TWIST1) repression.
|
29536528 |
2018 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Particularly, the sustained activation of epidermal growth factor receptor (EGFR), hedgehog, Wnt/β-catenin, Notch, hyaluronan (HA)/CD44 and stromal cell-derived factor-1 (SDF-1)/CXC chemokine receptor 4 (CXCR4) during the epithelial-mesenchymal transition (EMT) process may provide critical functions for PC progression to locally invasive, metastatic and androgen-independent disease states and treatment resistance.
|
21607288 |
2012 |
|
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Although the cellular origin of CaP in patients cannot be easily determined at present, the results imply that β-catenin inhibition is a potential therapeutic option for a subset of patients with basal-derived CaP.
|
25712462 |
2015 |